Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

featured

Published in COVID-19 and

Journal Scan / Research · April 05, 2020

There Is No Evidence to Abandon RAS Blockers During the COVID-19 Pandemic

Hypertension

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

Hypertension

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Hypertension 2020 Mar 25;[EPub Ahead of Print], AHJ Danser, M Epstein, D Batlle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

COVID-19

There Is No Evidence to Abandon RAS Blockers During the COVID-19 Pandemic

Additional Info

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Further Reading

The National Academies Report on Long-COVID

The Day the Pandemic Died

Managing Cardiovascular Sequelae in Long COVID-19

HFpEF and COVID at ACC 2023

A Seasonal Gift

COVID-19 Related Impact on Overall Adult Health and Wellbeing

PCP Approach to COVID-19–Associated Adult Psychosocial Health

COVID and the Patient With Rheumatoid Arthritis

COVID-19: Current Treatments

COVID-19: Mutations and New Variants

COVID-19 Related Impacts on Overall Child Health and Wellbeing

Recently Updated